肝癌合并门静脉癌栓治疗的瓶颈与对策

Bottleneck and strategies in the treatment of hepatocellular carcinoma with portal vein tumor thrombus

  • 摘要: 肝癌发生发展过程中易侵犯门静脉形成门静脉癌栓,由于预后极差且缺乏有效的治疗手段,是影响肝癌整体疗效提高的瓶颈。近年来,随着新治疗理念和方法的开展,门静脉癌栓的疗效有所提高,但仍存在诸多难点和瓶颈。如何统一各项治疗的适应证、如何创新诊断与治疗技术、如何进行多学科联合诊断与治疗和如何进行高质量循证医学研究等对提高肝癌合并门静脉癌栓患者疗效尤为重要。针对诸多瓶颈需要建立相应的策略,《肝细胞癌合并门静脉癌栓多学科诊治中国专家共识(2016版)》的发布为临床治疗和科研提供了有力的参考,研究者应开发新治疗手段、推广多学科综合治疗理念、开展高质量临床研究等以提高肝癌合并门静脉癌栓患者的整体疗效。

     

    Abstract: Hepatocellular carcinoma (HCC) is prone to invading portal vein system known as portal vein tumor thrombus (PVTT). PVTT is one of the main reasons for poor prognosis of HCC because of its rapid progress and lack of effective treatments. In recent years, with the development of new therapeutic concepts and methods, the curative effect of PVTT has been improved. But there are still many difficulties of treatment of PVTT: how to definite the indications of various treatment of PVTT, how to innovate treatment methods, how to carry out the multidisciplinary treatment and how to conduct high-quality evidence-based clinical research. The strategies need to be built for these bottlenecks. Chinese Expert Consensus on Multidisciplinary Diagnosis and Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus (2016 edition) also provided a powerful reference experience for clinical treatment and research. Researchers should develop new treatment methods, popularize the idea of multidisciplinary treatment and conduct high-quality evidence-based clinical research in the future to improve the curative effect of PVTT patients.

     

/

返回文章
返回